PharmAla Biotech Supports Decision to Decriminalize Possession of MDMA in British Columbia
PharmAla Biotech signs supply deal with Global Wellness Strategies to provide MDMA for trial
Psychedelics 101 | February 8, 2022
Expert Outlook 2021: Nick Kadysh
Rick Doblin, Exec. Director, MAPS & Nick Kadysh, President & CEO, PharmAla Biotech | MDMA Conference

Media Releases

Mindset Pharma and PharmAla Biotech Enter into Exclusive Sales Agreement

Posted: Nov. 16, 2022

PharmAla Submits Pre-IND Dossier for Novel MDMA Analog to FDA

Posted: Nov. 02, 2022

PharmAla appoints Dr. Leah Mayo to Scientific Advisory Board

Posted: Oct. 13, 2022

PharmAla Contracts with Clerkenwell to bring safer MDMA analogue to US, UK

Posted: Oct. 11, 2022

PharmAla Biotech ready to assist Alberta Government with Clinical MDMA supply

Posted: Oct. 06, 2022

PharmAla Biotech to supply University of California Clinical Trial with LaNeo™ MDMA

Posted: Oct. 05, 2022

PharmAla Biotech to supply University of Sydney Clinical Trial with LaNeo™️ MDMA

Posted: Aug. 31, 2022

PharmAla Biotech completes filing of patent application for 6 MDMA analogs

Posted: Aug. 29, 2022

PharmAla Biotech to supply Major Australian Research Institute with LaNeo™ MDMA for Phase 3 Clinical Trial

Posted: Aug. 22, 2022

PharmAla Biotech First Publicly Traded Company to Produce GMP MDMA

Posted: Aug. 15, 2022

PharmAla Biotech Applauds Sen. Cory Booker and Sen. Rand Paul's Bill to Include MDMA in "Right-to-Try" Legislation

Posted: Aug. 04, 2022

PharmAla Biotech appoints Kevin Roy to its Board of Directors

Posted: Jul. 04, 2022

PharmAla Biotech Registers Trademark for MDMA

Posted: Jun. 24, 2022

PharmAla Biotech Supports Decision to Decriminalize Possession of MDMA in British Columbia

Posted: Jun. 02, 2022

Psychedelics Canada Announces The Launch Of The First National Trade Association For Legal Psychedelics Companies

Posted: May 27, 2022

PharmAla Biotech & SABI Mind Announce MDMA Supply Agreement

Posted: May 19, 2022

PharmAla Biotech Expands MDMA Distribution with CCrest Labs

Posted: May 10, 2022

PharmAla Biotech to supply Mind Medicine Australia with GMP MDMA for Clinical Trial

Posted: Apr. 09, 2022

PharmAla Biotech adds David Purcell as Director of Sales

Posted: Mar. 14, 2022

PharmAla Biotech contracts with InterVivo Solutions to validate novel MDMA analogs

Posted: Mar. 07, 2022

Global Wellness Strategies Signs MDMA Supply Agreement with PharmAla Biotech

Posted: Feb. 10, 2022

PharmAla Biotech initiates research at the University of Arkansas for Medical Sciences

Posted: Jan. 17, 2022

PharmAla Biotech Announces Listing on the Canadian Securities Exchange

Posted: Jan. 10, 2022

Search Releases

Type keywords to filter the list of press releases:

Media Inquiries

Nicholas Kadysh, CEO